Natural compounds and the hypoxia-inducible factor (HIF) signalling pathway

Biochimie

Volumn 91, Issue 11-12, 2009, Pages 1347-1358

  Manolescu, Bogdan ^a   Oprea, Eliza ^b   Busu, Carmina ^a   Cercasov, Cornelia ^b  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

Cancer; Flavonoids; HIF; Hypoxia; Natural compounds

Indexed keywords

2 METHOXYESTRADIOL; 4' O METHYLALPINUMISOFLAVONE; 7 HYDROXYNEOLAMELLARIN; ALPINUMISOFLAVONE; APIGENIN; BAICALEIN; BAKUCHIOL; BENZOCHROMENONE DERIVATIVE; BENZOFURAN DERIVATIVE; CAMPTOTHECIN; CARDIAC GLYCOSIDE; CHRYSIN; CURCUMIN; DEGUELIN; DICARNOXIDE; DITERPENE; FLAVONOID; FUROSPONGOLIDE; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; LAMELLARIN O; LATRUNCULIN A; NEOLAMELLARIN DERIVATIVE; PLANT MEDICINAL PRODUCT; QUERCETIN; SESTERTERPENE; SILIBININ; TRITERPENOID; UNCLASSIFIED DRUG; UNINDEXED DRUG; VITEXIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; CANCER INHIBITION; COLORECTAL CARCINOMA; DRUG CYTOTOXICITY; DRUG STRUCTURE; GENE EXPRESSION REGULATION; GLIOMA; HUMAN; HYPOXIA; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; PROTEIN SYNTHESIS INHIBITION; RETINA NEOVASCULARIZATION; REVIEW; SIGNAL TRANSDUCTION; SOLID TUMOR;

BIOLOGICAL PRODUCTS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS;

EID: 73049091140     PISSN: 03009084     EISSN: 61831638     Source Type: Journal    
DOI: 10.1016/j.biochi.2009.08.005     Document Type: Review

References (115)

1. Semenza G.L. HIF-1 and human disease: one highly involved factor. Gen. Dev. 14 (2000) 1983-1991
2. Ke Q., and Costa M. Hypoxia-inducible factor-1 (HIF-1). Mol. Pharmacol. 70 (2006) 1469-1480
3. 2 homeostasis. Curr. Opin. Genet. Dev. 8 (1998) 588-594
4. 2 tension. Proc. Natl. Acad. Sci. USA 92 (1995) 5510-5514
5. Brahimi-Horn C., Mazure N., and Pouyssegur J. Signalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications. Cell Sign 17 (2005) 1-9
6. Hockel M., and Vaupel P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst. 93 (2001) 266-276
7. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin. Radiat. Oncol. 14 (2004) 198-206
8. Brown J.M., and Wilson W.R. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 4 (2004) 437-447
9. Graeber T.G., Osmanian C., Jacks T., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumors. Nature 379 (1996) 88-91
10. Zhong H., De Marzo A.M., Laughner E., et al. Overexpression of hypoxi-inducible factor 1α in common human cancers and their metastases. Cancer Res. 59 (1999) 5830-5835
11. Sohda M., Ishikawa H., Masuda N., et al. Pretreatment evaluation of combined HIF-1alpha, p53, and p21 expression is a useful and sensitive indicator of response to radiation and chemotherapy in esophageal cancer. Int. J. Cancer 110 (2004) 838-844
12. Theodoropoulos V.E., Lazaris A.C., Sofras F., et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur. Urol. 46 (2004) 200-208
13. 2 regulated prolyl hydroxylation. Science 292 (2001) 468-472
14. Hogenesch J.B., Chan W.K., Jackiw V.H., et al. Characterisation of a subset of the basic helix-loop-helix-PAS superfamily that interacts with components of the dioxin signalling pathway. J. Biol. Chem. 272 (1997) 8581-8593
15. Gu Y.Z., Moran S.M., Hogenesch J.B., et al. Molecular characterisation and chromosomal localisation of a third a-class hypoxia inducible factor subunit, HIF-3α. Gene Expr. 7 (1998) 205-213
16. Ruas J.L., Poellinger L., and Pereira T. Functional analysis of hypoxia-inducible factor-1 alpha-mediated transactivation. Identification of amino acid residues critical for transcription and/or interaction with CREB-binding protein. J. Biol. Chem. 277 (2002) 38723-38730
17. Lando D., Peet D.J., Whelan D.A., et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science 295 (2002) 858-861
18. C-Hu J., Sataur A., Wang L., et al. The N-terminal transactivation domain confers target gene specificity of hypoxia-inducible factors HIF-1α and HIF-2α. Mol. Biol. Cell 18 (2007) 4528-4542
19. Pugh C.W., O'Rourke J.F., Nagao M., et al. Activation of hypoxia-inducible factor-1; definition of regulatory domains within the α subunit. J. Biol. Chem. 272 (1997) 11205-11214
20. Schofield C.J., and Zhang Z. Structural and mechanistic studies on 2-oxoglutarate-dependent oxygenases and related enzymes. Curr. Opin. Struct. Biol. 9 (1999) 722-731
21. McNeil L.A., Hewiston K.S., Gleadle J.M., et al. The use of dioxygen by HIF prolyl hydroxylase (PHD1). Bioorg. Med. Chem. Lett. 12 (2002) 1547-1550
22. Walmsley S.R., McGovern N.N., Whyte M.K.B., et al. The HIF/VHL pathway. From oxygen sensing to innate immunity. Am. J. Resp. Cell Mol. Biol. 38 (2008) 251-255
23. Stiehl D.P., Wirthner R., Koditz J., et al. Increased prolyl 4-hydroxylase domain proteins compensate for decreased oxygen levels. J. Biol. Chem. 281 (2006) 23482-23491
24. Kaelin Jr. W.G., and Ratcliff P.J. Oxygen sensing by metazoas: the central role of the HIF hydroxylase pathway. Mol. Cell 30 (2008) 393-402
25. Maxwell P.H., Wiesener M.S., Chang G.W., et al. The tumor suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399 (1999) 271-275
26. Cockman M.E., Masson N., Mole D.R., et al. Hypoxia inducible factor-α binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275 (2000) 25733-25741
27. Ohh M., Park C.W., Ivan M., et al. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein. Nat. Cell Biol. 2 (2000) 423-427
28. Tanimoto K., Makino Y., Pereira T., et al. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein. EMBO J. 19 (2000) 4298-4309
29. Lando D., Peet D.J., Whelan D.A., et al. Asparagine hydroxylation of the HIF transactivation domain a hypoxic switch. Science (Wash., DC) 295 (2002) 858-861
30. Nakayama K., Few I.J., Hagensen M., et al. Siah2 regulates stability of prolyl-hydroxylases, controls HIF1alpha abundance, and modulates physiological response to hypoxia. Cell 117 (2004) 941-952
31. Fukuba H., Yamashita H., Nagano Y., et al. Siah-1 facilitates ubiquitination and degradation of factor inhibiting HIF-1alpha (FIH). Biochem. Biophys. Res. Commun. 353 (2007) 324-329
32. Appelhoff R.J., Tian Y.-M., Raval R.R., et al. Differential function of the prolyl hydroxylases PHD1, PHD2, and PHD3 in the regulation of hypoxia-inducible factor. J. Biol. Chem. 279 (2004) 38458-38465
33. Fukuba H., Takahashi T., Jin H.G., et al. Abundance of asparagynyl-hydroxylase FIH is regulated by Siah-1 under normoxic conditions. Neurosci. Lett. 433 (2008) 209-214
34. 2-regulated gene expression. FASEB J. 16 (2002) 1151-1162
35. Hirota K., and Semenza G.L. Regulation of angiogenesis by hypoxia-inducible factor 1. Crit. Rev. Oncol. Hematol. 59 (2006) 15-26
36. Metzen E., and Ratcliff P.J. HIF hydroxylation and cellular oxygen sensing. Biol. Chem. 385 (2004) 223-230
37. Bernardi R., Guernah I., Jin D., et al. PML inhibits HIF-1alpha translation and neoangiogenesis through repression of mTOR. Nature 442 (2006) 779-785
38. Richard D.E., Berra E., Gothie E., et al. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1α (HIF-1α) and enhance the transcriptional activity of HIF-1. J. Biol. Chem. 274 (1999) 32631-32637
39. Mylonis I., Chachami G., Samiotaki M., et al. Identification of MAPK phosphorylation sites and their role in the localization and activity of hypoxia-inducible factor-1α. J. Biol. Chem. 281 (2006) 33095-33106
40. Suzuki H., Tomida A., and Tsuruo T. Dephosphorylated hypoxia-inducible factor 1 alpha as a mediator of p53-dependent apoptosis during hypoxia. Oncogene 20 (2001) 5779-5788
41. Feldser D., Agani F., Iyer V., et al. Reciprocal positive regulation of hypoxia-inducible factor 1 α and insulin-like growth factor 2. Cancer Res. 59 (1999) 3915-3918
42. Wilson V.G., and Rosas-Acosta G. Wrestling with SUMO in a new arena. Sci. STKE 290 (2005) 10.1126/stke.2902005pe32
43. Bae S.H., Jeong J.W., Park J.A., et al. Sumoylation increases HIF-1alpha stability and its transcriptional activity. Biochem. Biophys. Res. Commun. 324 (2004) 394-400
44. Carbia-Nagashima A., Gerez J., Perez-Castro C., et al. RSUME, a small RWD-containing protein, enhances SUMO conjugation and stabilizes HIF-1alpha during hypoxia. Cell 131 (2007) 309-323
45. Berta M., Mazure N., Hattab M., et al. SUMOylation of hypoxia-inducible factor-1 alpha reduces its transcriptional activity. Biochem. Biophys. Res. Commun. 360 (2007) 646-652
46. Jeong J.W., Bae M.K., Ahn M.Y., et al. Regulation and destabilization of HIF-1α by ARD1-mediated acetylation. Cell 111 (2002) 709-720
47. Yang X.-J., and Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol. Cell Biol. 25 (2005) 2873-2884
48. Jeong J.W., Bae M.K., Ahn M.Y., et al. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111 (2002) 709-720
49. Fath D.M., Kong X., Liang D., et al. Histone deacetylase inhibitors repress the transactivation potential of hypoxia-inducible factors independently of direct acetylation of HIF-1α. J. Biol. Chem. 281 (2006) 13612-13619
50. Arnesen T., Kong X., Evjenth R., et al. Interaction between HIF-1alpha (ODD) and hARD1 does not induce acetylation and destabilization of HIF-1alpha. FEBS Lett. 579 (2005) 6428-6432
51. Sumbayev W., Budde A., Zhou J., et al. HIF-1 alpha protein as a target for S-nitrosation. FEBS Lett. 535 (2003) 106-112
52. Yasinska I.M., and Sumbayev W. S-nitrosation of Cys-800 of HIF-1alpha protein activates its interaction with p300 and stimulates its transcriptional activity. FEBS Lett. 549 (2003) 105-109
53. Kozhukhar A.V., Yasinska I.M., and Sumbayev S.S. Nitric oxide inhibits HIF-1alpha protein accumulation under hypoxic conditions: implication of 2-oxoglutarate and iron. Biochimie 88 (2006) 411-418
54. Sumbayev W., and Yasinska I.M. Peroxynitrite as an alternative donor of oxygen in HIF-1alpha proline hydroxylation under low oxygen availability. Free Radic. Res. 40 (2006) 631-635
55. Jones D.P. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol. 295 (2008) C849-C868
56. Giordano F.J. Oxygen, oxidative stress, hypoxia, and heart failure. J. Clin. Invest. 115 (2005) 500-508
57. Pialoux V., Mounier R., Brown A.D., et al. Relationship between oxidative stress and HIF-1 alpha mRNA during sustained hypoxia in humans. Free Radic. Biol. Med. 46 (2009) 321-326
58. Hoshikawa Y., Ono S., Suzuki S., et al. Generation of oxidative stress contributes to the development of pulmonary hypertension induced by hypoxia. Appl. Physiol. 90 (2001) 1299-1306
59. Galanis A., Pappa A., Giannakakis A., et al. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett. 266 (2008) 12-20
60. o site of the mitochondrial complex III is required for the transduction of hypoxic signalling via reactive oxygen species production. J. Cell Biol. 177 (2007) 1029-1036
61. Powis G., and Kirkpatrick L. Hypxia inducible factor-1α as a cancer drug target. Mol. Cancer Ther. 3 (2004) 647-654
62. Melillo G. Inhibiting hypoxia-inducible factor 1 for cancer therapy. Mol. Cancer Res. 4 (2006) 601-605
63. Nagle D.G., and Zhou Y.D. Natural product-based inhibitors of hypoxia-inducible factor-1 (HIF-1). Curr. Drug Targets 7 (2006) 355-369
64. Nagle D.G., and Zhou Y.D. Natural product-derived small molecule activators of hypoxia-inducible factor-1 (HIF-1). Curr. Pharm. Des 12 (2006) 2673-2688
65. Middleton Jr. E., Kandaswami C., and Theoharides T.C. The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. Pharmacol. Rev. 52 (2000) 673-751
66. Zhou Y.D., Kim Y.P., Li X.C., et al. Hypoxia-inducible factor-1 activation by (-)-epicatechin gallate: potential adverse effects of cancer chemoprevention with high-dose green tea extracts. J. Nat. Prod. 67 (2004) 2063-2069
67. Triantafyllou A., Liakos P., Tsakalof A., et al. The flavonoid quercetin induces hypoxia-inducible factor-1alpha (HIF-1alpha) and inhibits cell proliferation by depleting intracellular iron. Free Radic. Res. 41 (2007) 342-356
68. Jeon H., Kim H., Choi D., et al. Quercetin activates an angiogenic pathway, hypoxia inducible factor (HIF)-1-vascular endothelial growth factor, by inhibiting HIF-prolyl hydroxylase: a structural analysis of quercetin for inhibiting HIF-prolyl hydroxylase. Mol. Pharmacol. 71 (2007) 1676-1684
69. Park S.S., Bae I., and Lee Y.J. Flavonoids-induced accumulation of hypoxia-inducible factor (HIF)-1alpha/2alpha is mediated through chelation of iron. J. Cell Biochem. 103 (2008) 1989-1998
70. Triantafyllou A., Mylonis I., Simos G., et al. Flavonoids induce HIF-1α but impair its nuclear accumulation and activity. Free Radic. Biol. Med. 44 (2008) 657-670
71. Mirzoeva S., Kim N.D., Chiu K., et al. Inhibition of HIF-1 alpha and VEGF expression by the chemopreventive bioflavonoid apigenin is accompanied by Akt inhibition in human prostate carcinoma PC3-M cells. Mol. Carcinog. 47 (2008) 686-700
72. Fang J., Zhou Q., Liu L.-Z., et al. Apigenin inhibits tumor angiogenesis through decreasing HIF-1α and VEGF expression. Carcinogenesis 28 (2007) 858-864
73. Katschinski D.M., Le L., Heinrich D., et al. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1α is dependent on heat shock protein-90 activity. J. Biol. Chem. 277 (2002) 9262-9267
74. Choi H.J., Eun J.S., Kim B.G., et al. Vitexin, an HIF-1alpha inhibitor, has anti-metastatic potential in PC12 cells. Mol. Cells 22 (2006) 291-299
75. K-Chun H., Kosmeder J.W., Sun S., et al. Effects of deguelin on the phosphatidylinositol 3-kinase/Akt pathway and apoptosis in premalignant human bronchial epithelial cells. J. Natl. Cancer Inst. 95 (2003) 291-302
76. Kim W.-Y., Oh S.-H., and Lee H.-Y. Deguelin can sensitize the radioresistant cells through blocking HIF-1 and angiogenesis. AACR Meet. Abstr. 751 (Apr 2007) 2007
77. Yu Y.S., Kim J., Kim J., et al. Deguelin inhibits retinal neovascularization by down-regulation of HIF-1α in oxygen-induced retinopathy. Invest. Ophthalmol. Vis. Sci. Meet. Abstr. 49 (2008) 2632
78. Hwang K.Y., Oh Y.T., Yoon H., et al. Baicalein suppresses hypoxia-induced HIF-1alpha protein accumulation and activation through inhibition of reactive oxygen species and PI 3-kinase/Akt pathway in BV2 murine microglial cells. Neurosci. Lett. 444 (2008) 264-269
79. Cho H., Lee H.-Y., Ahn D.-R., et al. Baicalein induces functional hypoxia-inducible factor-1α and angiogenesis. Mol. Pharmacol. 74 (2008) 70-81
80. Fu B., Xue J., Li Z., et al. Chrysin inhibits expression of hypoxia-inducible factor-1α through reducing hypoxia-inducible factor-1α stability and inhibiting its protein synthesis. Mol. Cancer Ther. 6 (2007) 220-226
81. Liu Y., Veena C.K., Morgan J.B., et al. Methylalpinumisoflavone inhibits hypoxia-inducible factor-1 (HIF-1) activation by simultaneously targeting multiple pathways. J. Biol. Chem. 284 (2009) 5859-5868
82. Ito T., Warnken S.P., and May W.S. Protein synthesis inhibition by flavonoids: roles of eukaryotic initiation factor 2 alpha kinases. Biochem. Biophys. Res. Commun. 265 (1999) 589-594
83. Lee D.-H., and Lee Y.J. Quercetin suppresses hypoxia-induced accumulation of hypoxia-inducible factor-1α (HIF-1α) through inhibiting protein synthesis. J. Cell Biochem. (2008) 10.1002/jcb.21851
84. Singh R.P., Gu M., and Agarwal R. Silibinin inhibits colorectal cancer growth by inhibiting tumor cell proliferation and angiogenesis. Cancer Res. 68 (2008) 2043-2050
85. Dai J., Liu Y., Zhou Y.-D., et al. Benzochromenones from the marine crinoid Comantheria rotula inhibit hypoxia-inducible factor-1 (HIF-1) in cell-based reporter assays and differentially suppress the growth of certain tumor cell lines. J. Nat. Prod. 70 (2007) 1462-1466
86. Bae M.K., Kim S.H., Jeong J.W., et al. Curcumin inhibits hypoxia-induced angiogenesis via down-regulation of HIF-1. Oncol. Rep. 15 (2006) 1557-1562
87. Choi H., Chun Y.-S., Kim S.-W., et al. Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition. Mol. Pharmacol. 70 (2006) 1664-1671
88. Thomas S.L., Zhong D., Zhou W., et al. EF24, a novel curcumin analog, disrupts the microtubule cytoskeleton and inhibits HIF-1. Cell Cycle 7 (2008) 2409-2417
89. Cheng A.L., Hsu C.H., Lin J.K., et al. Phase I clinical of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 21 (2001) 2895-2900
90. Thomas S.L., O'Brate A.M., Malik S., et al. Anti-HIF activity of curcumin and analog EF24. AACR Meet. Abstr. (2006) 1348-1349
91. Kasman Y., Groweiss A., and Shmueli U. Latrunculin, a new 2-thiazolidinone macrolide from the marine sponge Latrunculia magnifica. Tetrahedron Lett. 21 (1980) 3629-3632
92. Wall M.E., Wani M.C., Cook C.E., et al. The isolation and structure of camptothecin, a novel alkaloidal leukaemia and tumor inhibitor from Camptotheca acuminate. J. Am. Chem. Soc. 88 (1966) 3888-3890
93. Aimi N., Nishimura M., Miwa A., et al. Pumiloside and deoxypumiloside; plausible intermediates of camptothecin biosynthesis. Tetrahedron Lett. 30 (1989) 4991-4994
94. Govindachari T.R., and Viswanathan N. Alkaloids of Mappia foetida. Phytochemistry 11 (1972) 3529-3531
95. Roja G., and Heble M.R. The quinoline alkaloids camptothecin and 9-methoxycamptothecin from tissue cultures and mature trees of Nothapodytes foetida. Phytochemistry 36 (1994) 65-66
96. Zhou B.-N., Hoch J.M., Johnson R.K., et al. Use of COMPARE analysis to discover new natural product drugs: isolation of camptothecin and 9-methoxycamptothecin from a new source. J. Nat. Prod. 63 (2000) 1273-1276
97. Klausmeyer P., McCloud T.G., Melillo G., et al. Identification of a new natural camptothecin analogue in targeted screening for HIF-1α inhibitors. Planta Med. 73 (2007) 49-52
98. Urban S., Butler M.S., and Capon R.J. Lamellarins O and P: new aromatic metabolites from the Australian marine sponge Dendrilla cactos. Aust. J. Chem. 47 (1994) 1919-1924
99. Liu R., Liu Y., Zhou Y.-D., et al. Molecular-targeted antitumor agents. 15. Neolamellarins from the marine sponge Dendrilla nigra inhibit hypoxia-inducible factor-1 activation and secreted vascular endothelial growth factor production in breast tumor cells. J. Nat. Prod. 70 (2007) 1741-1745
100. Dat N.T., Jin X., Lee J.-H., et al. Abietane diterpenes from Salvia miltiorrhiza inhibit the activation of hypoxia-inducible factor-1. J. Nat. Prod. 70 (2007) 1093-1097
101. Pages G., and Pouyssegur J. Transcriptional regulation of the vascular endothelial growth factor gene - a concert of activating factors. Cardiovasc. Res. 65 (2005) 564-573
102. Youssef D.T.A. Tasnemoxides A-C, new cytotoxic cyclic norsesterterpene peroxides from the red sea sponge Diacarnus erythraenus. J. Nat. Prod. 67 (2004) 112-114
103. Dai J., Liu Y., Zhou Y.-D., et al. Hypoxia-selective antitumor agents: norsesterterpene peroxides from the marine sponge Diacarnus levii preferentially suppress the growth of tumor cells under hypoxic conditions. J. Nat. Prod. 70 (2007) 130-133
104. Dai J., Liu Y., Zhou Y.-D., et al. Cytotoxic metabolites from an Indonesian sponge Lendenfeldia sp. J. Nat. Prod. 70 (2007) 1824-1826
105. Dai J., Fishback J.A., Zhou Y.-D., et al. Sodwanone and yardenone triterpenes from a South African species of the marine sponge Axinella inhibit hypoxia-inducible factor-1 (HIF-1) activation in both breast and prostate tumor cells. J. Nat. Prod. 69 (2006) 1715-1720
106. Liu Y., Liu R., Mao S.-C., et al. Molecular-targeted antitumor agents. 19. Furospongolide from a marine Lendenfeldia sp. sponge inhibits hypoxia-inducible factor-1 activation in breast tumor cells. J. Nat. Prod. 71 (2008) 1854-1860
107. C-Wu Z., Hong S.S., Cai X.F., et al. Hypoxia-inducible factor-1 and nuclear factor-kB inhibitory meroterpene analogues of bakuchiol, a constituent of the seeds of Psoralea coryfolia. Bioorg. Med. Chem. Lett. 18 (2008) 2619-2623
108. Wu C.-Z., Cai X.F., Dat N.T., et al. Bisbakuchiols A and B, novel dimeric meroterpenoids from Psoralea coryfolia. Tetrahedron Lett. 48 (2007) 8861-8864
109. Mabjeesh N.J., Escuin D., LaVallee T.M., et al. 2ME2 inhibits tumor growth and angiogenesis by disrupting microtubules and dysregulating HIF. Cancer Cell 3 (2003) 363-375
110. Chamaon K., Stojek J., Kanakis D., et al. Micromolar concentrations of 2-methoxyestradiol kill glioma cells by an apoptotic mechanism, without destroying their microtubule cytoskeleton. J. Neurooncol. 72 (2005) 11-16
111. Kang S.-H., Cho H.T., Devi S., et al. Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res. 66 (2006) 11991-11997
112. Schoner W., and Scheiner-Bobis G. Endogenous and exogenous cardiac glycosides: their roles in hypertension, and cell growth. Am. J. Physiol. Cell Physiol. 293 (2007) C509-C536
113. Zhang H., Qian D.Z., Tan Y.S., et al. Inaugural article: digoxin and other cardiac glycosides inhibit HIF-1 synthesis and block tumor growth. Proc. Natl. Acad. Sci. USA 105 (2008) 19579-19586
114. Klausmeyer P., Zhou Q., Scudiero D.A., et al. Cytotoxic and HIF-1alpha inhibitory compounds from Crossosoma bigelovii. J. Nat. Prod. 72 (2009) 805-812
115. Dat N.T., Jin X., Lee K., et al. Hypoxia-inducible factor-1 inhibitory benzofurans and chalcone-derived Diels-Alder adducts from Morus species. J. Nat. Prod. 72 (2009) 39-43